newsfilter
← Latest News
Business Wire·

enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones

  • enGene Therapeutics Inc. appointed Erik T. Goluboff, MD, MBA as Chief Medical Officer & Jason Duncan as Chief Legal and Administrative Officer effective November 9, 2026.
  • The appointments aim to strengthen the executive team ahead of a planned Biologics License Application (BLA) submission for detalimogene before year-end 2026 & anticipated approval in 2027.
  • Detalimogene is currently being evaluated in the multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying the drug in high-risk, BCG-unresponsive patients with carcinoma in situ (CIS).
  • The Board of Directors approved inducement equity grants of 450,000 stock options for Dr. Goluboff & 500,000 stock options for Mr. Duncan.
  • The stock options will vest over four years, with 25% vesting on November 13, 2027, & the remainder vesting in equal monthly amounts thereafter.
  • Dr. Goluboff brings over 30 years of experience in biotechnology, including roles at AstraZeneca, Genentech / Roche, & Tyra Biosciences, focusing on urologic oncology.
  • Mr. Duncan has more than two decades of experience in life sciences legal & operational roles, most recently serving as Chief Legal and Administrative Officer at Neumora Therapeutics.
  • Detalimogene is a non-viral gene therapy developed using the Dually Derivatized Oligochitosan (DDX) platform designed to elicit localized anti-tumor immune responses in non-muscle invasive bladder cancer (NMIBC).
  • The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) & Fast Track designations to detalimogene, & it is part of the CMC Development and Readiness Pilot program.
  • The LEGEND trial's pivotal cohort (Cohort 1) consists of 125 patients with high-risk, BCG-unresponsive NMIBC with CIS & is intended to form the basis of the BLA filing.
  • The company thanked interim Chief Medical Officer Dr. Bill Grossman for his contributions since June 2026.